Page 4 - David Bartel News Today

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 4,930,000 shares, a decline of 8.5% from the February 28th total of 5,390,000 shares. Based on an average daily volume of 781,100 shares, the days-to-cover ratio is currently 6.3 days. […]

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) have been given an average rating of “Moderate Buy” by the twenty-two research firms that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average […]

Verition Fund Management LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 4,827 shares of the biopharmaceutical company’s stock, valued at approximately $966,000. A number of other hedge funds have also […]

Sherry Nyeo, an MIT senior majoring in computer science and molecular biology, studies RNA and plans to pursue a career in biotechnology. She participates in NEET and MIT Biotech Group and advises students through the Undergraduate Research Opportunities Program (UROP).

 

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its target price boosted by research analysts at HC Wainwright from $350.00 to $400.00 in a report issued on Tuesday, The Fly reports. HC Wainwright’s target price suggests a potential upside of 154.08% from the stock’s current price. Several other equities analysts also recently weighed in on ALNY. […]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) has been assigned a consensus rating of “Buy” from the eighteen research firms that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 12-month target price among […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) – Investment analysts at Oppenheimer decreased their Q1 2022 earnings per share estimates for Alnylam Pharmaceuticals in a report issued on Monday, April 4th. Oppenheimer analyst L. Gershell now forecasts that the biopharmaceutical company will earn ($1.76) per share for the quarter, down from their previous estimate of […]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) Director Steven M. Paul sold 15,000 shares of the stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $170.69, for a total transaction of $2,560,350.00. The sale was disclosed in a filing with the SEC, which is available through this […]